Poniard To Presents Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial

Small Cell Lung Cancer Trial

Poniard Pharmaceuticals announced that data from a Phase 2 trial of picoplatin in patients with small cell lung cancer will be presented in a poster session at the 43rd Annual Meeting of the American Society of Clinical Oncology.

Details are as follows:

-- Abstract #7722, Poster #EE3

A Phase 2 study of picoplatin as second-line therapy for patients with small cell lung cancer who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum-containing chemotherapy.

In addition, two picoplatin abstracts have been selected for publication in the 2007 ASCO Proceedings and will be available online through asco.org. These abstracts include safety data from an ongoing Phase 1/2 study of picoplatin for the potential front-line treatment of colorectal cancer and from an ongoing Phase 1/2 study of picoplatin and docetaxel (Taxotere(R)) in chemotherapy-naive patients with metastatic hormone-refractory prostate cancer. Details are as follows:

-- Abstract #14510

Phase 1 study of picoplatin in combination with 5-fluorouracil and leucovorin as initial therapy in subjects with metastatic colorectal cancer.

-- Abstract #15546

Phase 1 study of picoplatin and docetaxel with prednisone in patients with chemotherapy-naive metastatic hormone refractory prostate cancer Roman L, Karlov P, Kaprin A, Gladkov O, Breitz H.

Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. It is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Poniard is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial in SCLC and in Phase 1/2 clinical trials in colorectal and

On May 1, 2007, the Company announced treatment of the first patient in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of intravenous picoplatin in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Poniard received orphan drug designation from the U.S. Food and Drug Administration in November 2005 for picoplatin for the treatment of SCLC. Poniard also is evaluating an oral formulation of picoplatin in a Phase 1 clinical trial.